JP2021534099A5 - - Google Patents

Info

Publication number
JP2021534099A5
JP2021534099A5 JP2021506624A JP2021506624A JP2021534099A5 JP 2021534099 A5 JP2021534099 A5 JP 2021534099A5 JP 2021506624 A JP2021506624 A JP 2021506624A JP 2021506624 A JP2021506624 A JP 2021506624A JP 2021534099 A5 JP2021534099 A5 JP 2021534099A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
perfluoro
hydrogen
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021506624A
Other languages
English (en)
Japanese (ja)
Other versions
JP7422737B2 (ja
JP2021534099A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/045229 external-priority patent/WO2020033359A1/en
Publication of JP2021534099A publication Critical patent/JP2021534099A/ja
Publication of JP2021534099A5 publication Critical patent/JP2021534099A5/ja
Priority to JP2024004449A priority Critical patent/JP2024056694A/ja
Application granted granted Critical
Publication of JP7422737B2 publication Critical patent/JP7422737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021506624A 2018-08-06 2019-08-06 神経変性疾患を治療するためのPpargc1a活性化剤としての2‐アリールベンゾイミダゾール Active JP7422737B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024004449A JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのPpargc1a活性化剤としての2‐アリールベンゾイミダゾール

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862714962P 2018-08-06 2018-08-06
US62/714,962 2018-08-06
PCT/US2019/045229 WO2020033359A1 (en) 2018-08-06 2019-08-06 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024004449A Division JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのPpargc1a活性化剤としての2‐アリールベンゾイミダゾール

Publications (3)

Publication Number Publication Date
JP2021534099A JP2021534099A (ja) 2021-12-09
JP2021534099A5 true JP2021534099A5 (cg-RX-API-DMAC7.html) 2022-08-12
JP7422737B2 JP7422737B2 (ja) 2024-01-26

Family

ID=69413327

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021506624A Active JP7422737B2 (ja) 2018-08-06 2019-08-06 神経変性疾患を治療するためのPpargc1a活性化剤としての2‐アリールベンゾイミダゾール
JP2024004449A Pending JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのPpargc1a活性化剤としての2‐アリールベンゾイミダゾール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024004449A Pending JP2024056694A (ja) 2018-08-06 2024-01-16 神経変性疾患を治療するためのPpargc1a活性化剤としての2‐アリールベンゾイミダゾール

Country Status (13)

Country Link
US (3) US12195432B2 (cg-RX-API-DMAC7.html)
EP (1) EP3833344A4 (cg-RX-API-DMAC7.html)
JP (2) JP7422737B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210068399A (cg-RX-API-DMAC7.html)
CN (2) CN119033775A (cg-RX-API-DMAC7.html)
AU (1) AU2019319745B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002165A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108773A1 (cg-RX-API-DMAC7.html)
IL (3) IL280664B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021001456A (cg-RX-API-DMAC7.html)
SG (1) SG11202101285YA (cg-RX-API-DMAC7.html)
TW (1) TWI904076B (cg-RX-API-DMAC7.html)
WO (1) WO2020033359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2830447T3 (es) 2015-12-15 2021-06-03 Univ Leland Stanford Junior Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
BR112021002165A2 (pt) 2018-08-06 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação
EP4118435A1 (en) * 2020-03-13 2023-01-18 Biorchestra Co., Ltd. Diagnostic methods using pgc-1? expression
CN112933232A (zh) * 2021-02-02 2021-06-11 袁玉佳 PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用
CN118541152A (zh) * 2021-11-02 2024-08-23 特朗奎斯治疗股份有限公司 具有循环髓样细胞炎性表型的受试者的选择和治疗
US20250262189A1 (en) * 2022-04-22 2025-08-21 Rdiscovery, LLC Treatment of diseases associated with reductive stress
CN120752039A (zh) * 2022-11-18 2025-10-03 五条聪 Zln-005和相关化合物的用途
US20260199293A1 (en) * 2022-12-02 2026-07-16 Tranquis Therapeutics, Inc. 2-Arylbenzimidazole Compounds for the Treatment of Hemoglobinopathies

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL275435A (cg-RX-API-DMAC7.html) * 1961-03-01
FR1569337A (cg-RX-API-DMAC7.html) * 1968-06-18 1969-05-30
US4038396A (en) 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
GB1584296A (en) * 1976-12-07 1981-02-11 Kanebo Ltd 2-substituted benzimidazole compounds
NZ234564A (en) 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
JPH09169729A (ja) * 1995-12-19 1997-06-30 Green Cross Corp:The 非ペプチド型インターロイキン8拮抗剤
CA2258728C (en) * 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
JP2000143635A (ja) * 1998-06-10 2000-05-26 Takeda Chem Ind Ltd 血管新生阻害剤
JP2000095767A (ja) * 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
TR200101239T2 (tr) * 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
JP2004515496A (ja) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
DE10134775A1 (de) * 2001-07-06 2003-01-30 Schering Ag 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
BRPI0512239A (pt) 2004-06-17 2008-02-19 Wyeth Corp processos para preparação de antagonistas de receptores de hormÈnios liberadores de gonatropina
WO2006122546A1 (de) 2005-05-18 2006-11-23 Forschungsverbund Berlin E.V. Nicht-peptidische inhibitoren der akap-pka-wechselwirkung
CA2616512A1 (en) 2005-07-28 2007-02-08 Intervet International B.V. Novel benzimidazole (thio) carbamates with antiparasitic activity and the synthesis thereof
US7345178B2 (en) 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2008059026A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
GB0807103D0 (en) 2008-04-18 2008-05-21 Univ Bradford The Compounds
US8835648B2 (en) * 2009-06-11 2014-09-16 Siena Biotech S.P.A. Hedgehog pathway antagonists and therapeutic applications thereof
WO2011047129A1 (en) 2009-10-15 2011-04-21 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
MX2012005248A (es) * 2009-11-06 2012-06-14 Univ Vanderbilt Aril- y heteroaril-sulfonas como potenciadores alostericos de mglur4, composiciones y metodos de tratamiento de la disfuncion neurologica.
GB201009656D0 (en) * 2010-06-09 2010-07-21 Univ St Andrews Carboxylation catalysts
JP5083393B2 (ja) 2010-09-16 2012-11-28 カシオ計算機株式会社 画像表示装置及びプログラム
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2012118935A1 (en) 2011-03-03 2012-09-07 Proteotech Inc Compounds for the treatment of neurodegenerative diseases
CN104662018B (zh) 2012-04-20 2017-10-24 阿迪维纳斯治疗有限公司 取代的杂双环化合物、组合物及其医疗应用
WO2014037340A1 (de) * 2012-09-05 2014-03-13 Bayer Cropscience Ag Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress
KR101435496B1 (ko) 2012-10-22 2014-08-28 한국과학기술연구원 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체
GB201302927D0 (en) * 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
CN103113307B (zh) * 2013-02-27 2015-08-05 南京大学 苯并咪唑类化合物及其应用
US10022357B2 (en) 2013-04-29 2018-07-17 The General Hospital Corporation Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease
WO2016061190A1 (en) 2014-10-14 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Method for treating neurodegenerative diseases
CN104873500A (zh) 2015-04-29 2015-09-02 中国人民解放军第四军医大学 化合物zln005的用途
EP3294715B1 (en) 2015-05-11 2020-05-06 Kancera AB Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
ES2830447T3 (es) * 2015-12-15 2021-06-03 Univ Leland Stanford Junior Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación
CN108602812B (zh) 2015-12-22 2021-11-02 坎塞拉有限公司 可用作哺乳动物组蛋白去乙酰化酶活性的抑制剂的双环异羟肟酸类化合物
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩
BR112021002165A2 (pt) 2018-08-06 2021-05-04 The Board Of Trustees Of The Leland Stanford Junior University composto, composição farmacêutica, e, métodos para tratar uma doença neurodegenerativa e deficiência cognitiva associada ao envelhecimento e neuroinflamação

Similar Documents

Publication Publication Date Title
JP5255983B2 (ja) カルバペネム系抗生物質、組成物及び調製方法
JP2020507589A5 (cg-RX-API-DMAC7.html)
MXPA01006474A (es) Derivados colquinol como agentes perjudiciales vasculares.
WO2009039981A3 (en) Use of (arg 8) vasopressin to treat eg s. pneumoniae infection
JP2023512501A5 (cg-RX-API-DMAC7.html)
IT1252868B (it) Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
JP2022527556A5 (cg-RX-API-DMAC7.html)
TW201619142A (zh) 利用替唑尼特(tizoxanide)、其類似物或鹽類之前驅藥的組成物及治療方法
AU2002359164A8 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
WO2009033665A3 (en) Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent
IL187183A0 (en) Pharmaceutical formulation of apomorphine for buccal administration
WO2009033785A3 (en) Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
WO1994020063A3 (en) Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
UA98462C2 (ru) Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
JP2015521617A5 (cg-RX-API-DMAC7.html)
RU2007101653A (ru) Производные 1-азабицикло[3.3.1]нонанов
EP2849738A1 (en) High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
SE9901573D0 (sv) New compounds
AU2016246802A1 (en) Boron-containing small molecules as antiprotozoal agents
JP5297815B2 (ja) 医薬組成物
DE2964903D1 (en) 2-lower alkyl-7-substituted-2 or 3-cephem-4-carboxylic acid compounds, processes for their preparation and pharmaceutical compositions containing them
JP2003522786A5 (cg-RX-API-DMAC7.html)
JP2004026678A (ja) 2型糖尿病治療剤
EP2909216B1 (en) Compositions and methods for improving glucose uptake
EP3931205A1 (en) Antibacterial peptides and methods of use